1 / 27

Content

AIFA European Conference on Clinical Research for Decision Making Which Medicines Do We Need ? Thomas Lönngren, EMEA 30 March 2007. Content. What are the health trends in EU ? Demographics Disease patterns Assessing the needs for medicines

lora
Download Presentation

Content

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AIFAEuropean Conference on Clinical Research for Decision Making Which Medicines Do We Need ?Thomas Lönngren, EMEA 30 March 2007

  2. Content • What are the health trends in EU ? • Demographics • Disease patterns • Assessing the needs for medicines • WHO report Priority Medicines for Europe and the world • How will decide on the medicines we need ? • EMEA role in the need of medicines • Conclusion

  3. Demographics • We are getting older • Number of over 80 year olds in EU 15 will increase dramatically over next 15 years • Difference between EU 15 and EU 10 • Ratio of pensioners to workers will have economic and social consequences • Higher cost of health care and medicines is to be expected

  4. Demographics

  5. Disease patterns • Burden of disease • Mental 23%,CVD 17%,Cancer 16.7 ,Injuries 11%, Respiratory 7.8 • Mortality • CVD 42%, Cancer 27%, Injuries 5.2, Mental 4.2% • Difference between EU countries • Example Tuberculosis

  6. TB Incidence

  7. Assessing the needs for medicines • WHO report Priority Medicines for Europe and the World • Methodology • Findings

  8. WHO methodology Burden of disease ranking EU10, EU25 The world (including EU25) Cochrane database of systematic reviews Clinical efficacy Projections and trends PRELIMINARY LIST OF PRIORITY DISEASES AND GAPS Social solidarity IN DEPTH REVIEWS OF PRELIMINARY LIST OF DISEASES AND GAPS FINAL REPORT

  9. WHO methodology • What is the size and nature of the disease burden? • What is the control strategy? • Why does the disease burden persist? • What wan be learnt from past/current research into pharmaceutical • interventions for this condition? • What is the current “pipeline” of products that are to be used for this • particular condition? • What are the opportunities for research into new pharmaceutical interventions? • What are the gaps between current research and potential research issues • which could make a difference, are affordable and could be carried out in • a) five years or b) in the longer term? • For which of these gaps are there opportunities for pharmaceutical research?

  10. Findings on the pharmaceutical gaps • Infections due to antibacterial resistance • Pandemic influenza • Cardiovascular disease (secondary prevention) • Diabetes (Type 1 and Type 2) • Cancer • Acute stroke • HIV/AIDS • Tuberculosis • Neglected diseases • Malaria • Alzheimer disease • Osteoarthritis • Chronic obstructive pulmonary disease • Alcohol use disorders: alcoholic liver diseases and alcohol dependency • Depression in the elderly and adolescents • Postpartum haemorrhage

  11. Submission of MAA through the Centralised Process are likely to come in phases for key indications Obesity: some development targeting both lipid and CNS pathways Alzheimer’s disease: extensive development including potential disease modifiers Influenza: continued submission of Core Dossier, Pre-pandemic and Seasonal influenza vaccines Insomnia: compounds targeting Serotinergic, GABA and Melatonin pathways Rheumatoid arthritis: multiple biological therapies using novel mechanisms Schizophrenia: compounds targeting combination of Serotinergic and Dopaminergic pathways Chronic Obstructive Pulmonary Disease/Asthma: multiple novel mechanisms, many as combinations Parkinson’s: possible generics, few novel mechanisms Pain: multiple novel mechanisms and generic MAA Oncology: multiple submissions, multiple indications. Increased number of biologicals including therapeutic antibodies, transfected cells, fusion proteins and DNA vaccines Hypertension: multiple submissions per year, third of which could be generic. Large number of combinations Type II Diabetes: novel classes including ‘Gliptins’ and Glucagon-Like Peptide-1 (GLP-1) receptor agonists. Developed as monotherapies and combinations 2007 2008 2009 2010

  12. Who decides on the medicines we need? • Policy makers, EU institutions and individual governments • Research-based pharmaceutical industry • Regulatory agencies for market approval • Pricing and reimbursement authorities • Health care systems and prescribers • Patients

  13. Policy makers, EU institutions and individual governments • They are setting the overall scene • In EU pharmaceutical policy proposed by the European Commission and decided by European Parliament and Council, e.g. DG SANCO public health programme • Do not cover healthcare and pricing and reimbursements - national responsibility • EU regulation is based on presumption that commercial forces will supply the medicines we need • Where the market does not deliver, then targeted action is taken, e.g. orphan drugs, paediatrics and Article 58 • DG Research 7th framework programme gives directions on priority areas of research

  14. Research-based pharmaceutical industry • Drivers for decision-taking • Scientific opportunities • Market assessment and return on investment • Availability and required resources • Medical need • Industry dilemma and challenge • Failure/attrition rate • High price for new medicines • Reward for innovation and price pressure • Will the industry deliver the medicines we need?

  15. Challenges

  16. Regulatory agencies for market approval • Decision on market approval based on quality, safety and efficacy • Relative efficacy (comparative clinical trials) • 20-25% of applications will not get market approval • Are the approved medicines the medicines we need?

  17. Pricing and reimbursement authorities • Different systems and criteria in EU Member States • No EU harmonisation/competence • Decision based on ? and relative effectiveness and cost effectiveness • Will their decisions secure access to medicines we need • (Un)Equal access in EU

  18. Health care systems and prescribers • Health technology assessments • Example NICE in UK • Recommendation of use within NHS • Regional and local drug committees • Recommendation on list of medicines for use • Local responsibilities for budget • Forcing hard priorities • What is the criteria's for decision making? • Prescribers have the final decision on witch medicines we need

  19. Patients • Historical patients passive in decision on therapy • Probably a dramatic change in the future • Budget constrains and priorities will make patients and there organisation more active • Publication of clinical trials will create a demand for early access to new medicines • Availability of information (Internet) • Patients participate in benefit risk assessment • Patients will move where they could receive the treatment

  20. EMEA role in the need of medicines Research-based industry, not regulators (incl. EMEA) select therapeutic areas of interest and make individual drug development decisions However, regulators (and legislators) proactively facilitate and influence drug development by: • Setting regulatory and scientific standards, making regulatory decision more predictable • Introduce incentives (e.g. orphan drugs, paediatric drugs, SMEs) • Specific collaborative programs: EMEA Road map 2010 ,US FDA critical path initiative, EU commission and industries initiative IMI

  21. EMEA roadmap 2010 • Safety of medicinal products • Earlier availability of new medicinal products • Support to innovation • Transparency, communication and provision of information • Reinforcing the EU medicines network

  22. Rapid access to new medicinal products and Support to innovation • New regulatory tools for access • Conditional MA and accelerate assessment • Risk management plans • Benefit risk assessment more consistency and predictability • Support to innovation • How to met the demand from a rapid scientific development • Scientific advice in drug development • Urgent public health needs • Pandemic influenza vaccines

  23. EMEA support to IMI Initiatives • The Innovative Medicine Initiative (IMI) • Part of the 7th Research framework program • Promote development innovative therapies • Partners: EU Commission, Academia, Patients Associations, EU Industry (including SMEs), Regulatory Authorities • Objectives: to make development process faster, efficient (reduce attrition), predictable and cheaper

  24. IMI Initiative

  25. IMI Initiative

  26. Conclusion • A shift to a growing elderly population will create a high need for health care in EU and need for new treatments • Important to monitor the development of new medicines and identify gaps and needs • If not market forces will fill the gaps governments or none profit organisations need to intervene • Decision making and criteria's for regulatory approval is well defined with a long tradition and history • Post approval decisions on different levels in member state is not harmonised leading to difference in availability • A priority for EMEA is to support accesses to medicines and stimulate drug development • Innovative medicine initiative (IMI )will contribute to an improved drug development process

More Related